Ocular Therapeutix Enters Quiet Period Ahead of SOL-1 Milestone

The latest announcement is out from Ocular Therapeutix ( (OCUL) ).

On December 18, 2025, Ocular Therapeutix announced it will enter a quiet period starting December 20, 2025 as it prepares for database lock of its SOL-1 Phase 3 clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of wet age-related macular degeneration. The company said its next investor communication is planned for early February 2026, tied to the release of fourth-quarter and full-year 2025 financial results, when it also expects to update investors on the timing of SOL-1 trial data, which remains scheduled for the first quarter of 2026, signaling a potentially important near-term clinical and strategic milestone for stakeholders.

The most recent analyst rating on (OCUL) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Ocular Therapeutix stock, see the OCUL Stock Forecast page.

Spark’s Take on OCUL Stock

According to Spark, TipRanks’ AI Analyst, OCUL is a Neutral.

Ocular Therapeutix’s overall stock score is primarily impacted by its financial challenges, including declining revenues and persistent losses. However, the company’s strategic initiatives, such as the NDA submission and stock offering, provide a positive outlook. The technical analysis suggests a bullish trend, but caution is advised due to overbought conditions. The earnings call and corporate events further support a moderate positive sentiment.

To see Spark’s full report on OCUL stock, click here.

More about Ocular Therapeutix

Ocular Therapeutix is a biopharmaceutical company focused on developing ophthalmic therapies, including drug-eluting treatments for retinal diseases such as wet age-related macular degeneration.

Average Trading Volume: 3,218,920

Technical Sentiment Signal: Strong Buy

Current Market Cap: $3.07B

For an in-depth examination of OCUL stock, go to TipRanks’ Overview page.